This article explains, in educational terms, radiofrequency ablation liver tumor — how the technology works and where it fits. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding.
Radiofrequency Ablation (RFA) for Liver Tumors
Radiofrequency ablation passes a high-frequency alternating current from an electrode into surrounding tissue, where ionic agitation generates resistive heat that is intended to coagulate a targeted tumor volume. For hepatocellular carcinoma, RFA is one of the most studied thermal techniques and is commonly performed under ultrasound or CT guidance in appropriately selected patients. INVAMED's Peta Radiofrequency Ablation (RFA) System is a generator-based ablation platform offered in variants for soft-tissue and liver tumor ablation as well as nerve (pain) ablation, and the multi-application ThermoEdge RFA Platform is positioned for liver and kidney tissue resection, cysts, and endometrial ablation. Achieving an adequate ablation margin around the tumor is a recognized goal in the literature, and the treating clinician judges whether a single or overlapping-ablation approach is warranted.
Design and Technical Notes
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions. For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
Key Considerations
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Frequently Asked Questions
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Related on INVAMED
- Oncology Ablation — product category
- Intracavitary Hypothermia for Bladder Cancer Explained — A Technical Guide
- Cryoablation vs Microwave ablation: What Is the Difference?
- Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors — Technical Overview
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.